Unknown

Dataset Information

0

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.


ABSTRACT:

Introduction

Estrogen receptor-? (ER) and human epidermal growth factor receptor 2 (HER2) positivity are inversely correlated by standard criteria. However, we investigated the quantitative relation between ER and HER2 expression at both RNA and protein levels in HER2+ve and HER2-ve breast carcinomas.

Methods

ER and HER2 levels were assessed with immunohistochemistry (IHC) and (for HER2) fluorescent in situ hybridization (FISH) and by quantitative reverse transcription-polymerase chain reaction (q-RT-PCR) in formalin-fixed primary breast cancers from 448 patients in the National Cancer Research Institute (NCRI) Adjuvant Breast Cancer Trial (ABC) tamoxifen-only arm. Relations at the RNA level were assessed in 1,139 TransATAC tumors.

Results

ER and HER2 RNA levels were negatively correlated as expected in HER2+ve (IHC 3+ and/or FISH-amplified) tumors (r = -0.45; P = 0.0028). However, in HER2-ve tumors (ER+ve and ER-ve combined), a significant positive correlation was found (r = 0.43; P < 0.0001), HER2 RNA levels being 1.74-fold higher in ER+ve versus ER-ve tumors. This correlation was maintained in the ER+veHER2-ve subgroup (r = 0.24; P = 0.0023) and confirmed in this subgroup in 1,139 TransATAC tumours (r = 0.25; P < 0.0001). The positive relation extended to IHC-detected ER in ABC: mean ± 95% confidence interval (CI) H-scores were 90 ± 19 and 134 ± 19 for 0 and 1+ HER2 IHC categories, respectively (P = 0.0013). A trend toward lower relapse-free survival (RFS) was observed in patients with the lowest levels of ER and HER2 RNA levels within the ER+veHER2-ve subgroup both for ABC and TransATAC cohorts.

Conclusions

ER and HER2 expression is positively correlated in HER2-ve tumors. The distinction between HER2+ve and HER2-ve is greater in ER-ve than in ER+ve tumors. These findings are important to consider in clinical trials of anti-HER2 and anti-endocrine therapy in HER2-ve disease.

Trial registration

Clinical trial identifier: ISRCTN31514446.

SUBMITTER: Pinhel I 

PROVIDER: S-EPMC3446380 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.

Pinhel Isabel I   Hills Margaret M   Drury Suzanne S   Salter Janine J   Sumo Georges G   A'Hern Roger R   Bliss Judith M JM   Sestak Ivana I   Cuzick Jack J   Barrett-Lee Peter P   Harris Adrian A   Dowsett Mitch M  

Breast cancer research : BCR 20120314 2


<h4>Introduction</h4>Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivity are inversely correlated by standard criteria. However, we investigated the quantitative relation between ER and HER2 expression at both RNA and protein levels in HER2+ve and HER2-ve breast carcinomas.<h4>Methods</h4>ER and HER2 levels were assessed with immunohistochemistry (IHC) and (for HER2) fluorescent in situ hybridization (FISH) and by quantitative reverse transcription-polymerase  ...[more]

Similar Datasets

| S-EPMC4396031 | biostudies-literature
| S-EPMC8001650 | biostudies-literature
| S-EPMC4327899 | biostudies-literature
| S-EPMC7218915 | biostudies-literature
| S-EPMC4462184 | biostudies-literature
| S-EPMC7409266 | biostudies-literature
| S-EPMC2722050 | biostudies-other
| S-EPMC7347802 | biostudies-literature
| S-EPMC8623301 | biostudies-literature
| S-EPMC3928099 | biostudies-literature